Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Onyx Pharmaceuticals: Focus Is a Double-edged Sword

This article was originally published in Start Up

Executive Summary

Onyx Pharmaceuticals announced last June that it would focus solely on its lead product candidate, BAY 43-9006, in Phase III and partnered with Bayer. Its stock has since soared. The company is responsible for some development, and so maintains an active clinical capability. It also negotiated a US co-promotion right. Both may make it an attractive in-licensor, but more than infrastructure, its greatest validation and attraction will come from showing that management made the right choice in prioritizing. It's an all-or-nothing bet, to be sure.

Related Content


Related Companies

Related Deals




Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts